Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (SHE:301246)

China · Delayed Price · Currency is CNY

15.24

-0.44 (-2.81%)

At close: Nov 13, 2026

Market Cap	6.05B -30.7%
Revenue (ttm)	2.56B +45.2%
Net Income	304.39M +2,040.2%
EPS	0.76 +2,009.4%
Shares Out	396.81M
PE Ratio	20.02
Forward PE	n/a
Dividend	0.05 (0.33%)
Ex-Dividend Date	Jun 26, 2026

Volume	4,799,650
Open	15.66
Previous Close	15.68
Day's Range	15.22 - 15.90
52-Week Range	14.86 - 35.58
Beta	1.05
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About SHE:301246

Hubei Hongyuan Pharmaceutical Technology Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical products in China, Asia, Europe, Africa, the Americas and internationally. The company offers active pharmaceutical ingredients, such as metronidazole, benzoyl metronidazole, dimetrizole, and acyclovir; pharmaceutical intermediates, including imidazole, glyoxylic acid, 2-methyl imidazole, 2-methyl-5-nitroimidazole, sulfate, guanine, diacetyl guanine, and diacetylacyclovir; organic chemical raw materials comprising glyoxal, and o... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 2,258

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301246

Full Company Profile

Financial Performance

In 2025, SHE:301246's revenue was 1.94 billion, an increase of 9.53% compared to the previous year's 1.77 billion. Earnings were 119.05 million, an increase of 131.33%.

Financial Statements